Conventional dose CRRT
Phase 3Small molecule
Conventional dose CRRT is one of 78 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1NORADRENALIN
UUniversity of Aarhus
Phase 3
Nicotinamide Treatment
AAssistance Publique - Hôpitaux de Paris
Phase 3
Conventional dose CRRT
SSeoul National University Hospital
Phase 3
Crestor
AstraZenecaPreclinical
L-Alanyl/l-Glutamine
TTemple Therapeutics BV
Phase 3
Pentoxyphylline
NNational Taiwan University Hospital
Phase 3
Proamatine
TakedaPreclinical
Lexapro
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome1 trial
Contrast Agent1 trial
Neuromuscular Blockade1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conventional dose CRRT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details